35588-36-4

Usage

Uses

Used in Chemical Synthesis:
2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE is used as a building block for the synthesis of more complex organic molecules, due to its unique structure and reactivity.
Used in Pharmaceutical Industry:
2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE is used as an intermediate in the development of pharmaceutical compounds, leveraging its chemical properties to create new drugs with potential therapeutic applications.
Safety Precautions:
It is essential to handle 2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE with care, as it may pose health hazards if not used properly. Appropriate safety measures, including personal protective equipment and proper disposal methods, should be taken when working with this chemical compound.

InChI:InChI=1/C9H9ClN2O3/c1-6-2-3-7(12(14)15)4-8(6)11-9(13)5-10/h2-4H,5H2,1H3,(H,11,13)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 99-55-8 2-methyl-5-nitroaniline 

Relevant academic research and scientific papers

Discovery of 4 H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models

Diabetic retinopathy (DR) is a major cause of blindness, and there is a lack of effective treatment at present. Rho-associated coiled-coil containing serine/threonine protein kinases (ROCKs) have recently been suggested as potential targets for the DR treatment. We herein report the discovery of 4H-chromen-4-one derivatives as a new class of ROCK inhibitors. Structure-activity relationship analyses led to the identification of the most active compound, 4-(dimethylamino)-N-(3-{2-[(4-oxo-4H-chromen-7-yl)oxy]acetamido}phenyl) (12j). This compound showed excellent kinase selectivity for ROCK I and ROCK II against 387 other kinases. In retinal explants, compound 12j protected retinal neurons from high glucose-induced oxidative stress and apoptosis-mediated cell death. Furthermore, 12j administration suppressed the improper proliferation of Müller cells and promoted the regression of vascular vessels in retinal explants cultured in a high glucose microenvironment. Collectively, our data suggest that 12j could be a potential lead compound for the treatment of DR, hence deserving further in-depth studies.

NOVEL COMPOUNDS

The present invention relates substituted N-biphenyl-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-biphenyl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

NOVEL COMPOUNDS

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N- [3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula(I) as described and defined herein,to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.